Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge, Natalie Staplin, KJ Mayne, Christoph Wanner et autres
BackgroundThe EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression.We aimed to assess how effects of empagliflozin might differ by primary …
in, gb, de, us (code pays fourni par la source)